Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says. Watch here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOncimmune Regulatory News (ONC)

  • This share is currently suspended. It was suspended at a price of 1.2699
  • There is currently no data for ONC

Total Voting Rights

6 Jan 2021 10:27

RNS Number : 7656K
Oncimmune Holdings PLC
06 January 2021
Β 

6 January 2021

Β 

Β 

Oncimmune Holdings plc

Β 

("Oncimmune" or the "Company")

Β 

Total Voting Rights

Β 

Β 

In accordance with the Disclosure Guidance and Transparency Rules (DTR 5.6), Oncimmune makes the following disclosure with respect to the share capital and voting rights of the Company.

Β 

As at 31 December 2020, the Company's issued share capital was 63,662,446 ordinary shares of Β£0.01 each with voting rights. The Company does not hold any shares in treasury.

Β 

The above figure of 63,662,446 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in the Company under the FCA's Disclosure Guidance and Transparency Rules.

Β 

Β 

Β 

For further information:

Β 

Oncimmune Holdings plc

Ron Kirschner, Company Secretary

contact@oncimmune.co.uk

Β 

Zeus Capital Limited (Nominated Adviser and Joint Broker)

Andrew Jones, Daniel Harris, Victoria Ayton

+44 (0)20 3829 5000

Β 

N+1 Singer (Joint Broker)

Aubrey Powell, Harry Gooden, Iqra Amin, James Fischer

+44 (0)20 7496 3000

Β 

WG Partners (Joint Broker)

David Wilson, Chris Lee

+44 (0)203 705 9321

Β 

Media enquiries:

FTI Consulting

Ben Atwell, Michael Trace, Alex Davis

Oncimmune@fticonsulting.com

+44 (0)20 3727 1000

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Β 
END
Β 
Β 
TVREAEFKEAKFEFA
Date   Source Headline
20th May 202212:11 pmRNSHolding(s) in Company
18th May 202211:46 amRNSHolding(s) in Company
5th May 20225:32 pmRNSHolding(s) in Company
3rd May 20226:10 pmRNSHolding(s) in Company
26th Apr 20224:26 pmRNSHolding(s) in Company
21st Apr 20227:00 amRNSQueen’s Award for Enterprise in Innovation 2022
14th Apr 202212:24 pmRNSExercise of Options, PDMR Dealing and TVR
8th Apr 20227:00 amRNSTwo further ImmunoINSIGHTS contracts signed
4th Apr 20222:43 pmRNSHolding(s) in Company
29th Mar 20224:46 pmRNSExercise of Options, PDMR Dealing and TVR
18th Mar 20223:01 pmRNSHolding(s) in Company
16th Mar 20227:00 amRNSBlock Listing Six Monthly Return
15th Mar 20227:00 amRNSExercise of Warrants and Total Voting Rights
9th Mar 20224:08 pmRNSHolding(s) in Company
7th Mar 20222:10 pmRNSPDMR Dealing
7th Mar 20227:00 amRNSFollow-on contract to validate previous profiling
4th Mar 20227:00 amRNSImmunoINSIGHTS contract signed with global pharma
1st Mar 20227:00 amRNSImmunoINSIGHTS and Synexa partnership
28th Feb 20227:05 amRNSInterim Results
28th Feb 20227:00 amRNSContract signed with Verily Life Sciences
25th Feb 20227:00 amRNSNotice of Half Year Results
21st Feb 20223:14 pmRNSHolding(s) in Company
17th Feb 20227:00 amRNSEarlyCDT Lung approved and adopted in Aragon Spain
15th Feb 20227:00 amRNSImmunoINSIGHTS commercial update
31st Dec 20217:00 amRNSResults from COVID-19 autoantibody profiling panel
24th Dec 20217:00 amRNSPDMR Dealing
22nd Dec 202111:10 amRNSGrant of Options and PDMR Dealing
21st Dec 202111:34 amRNSPDMR Dealing
21st Dec 20217:00 amRNSImmunoINSIGHTS commercial update
20th Dec 20213:13 pmRNSTotal Voting Rights
7th Dec 20217:00 amRNSCommercial momentum in ImmunoINSIGHTS
26th Nov 20214:41 pmRNSSecond Price Monitoring Extn
26th Nov 20214:36 pmRNSPrice Monitoring Extension
26th Nov 202110:36 amRNSResults of Annual General Meeting
3rd Nov 20217:00 amRNSNotice of AGM and posting of Annual Report
2nd Nov 20217:00 amRNSFull year results and progress update
2nd Nov 20217:00 amRNSChange of Adviser
27th Oct 20214:35 pmRNSPrice Monitoring Extension
25th Oct 20214:40 pmRNSSecond Price Monitoring Extn
25th Oct 20214:35 pmRNSPrice Monitoring Extension
25th Oct 20217:00 amRNSNotice of Full Year results
20th Sep 20217:00 amRNSAgreement with pharma company to profile patients
15th Sep 202111:08 amRNSBlock Listing Six Monthly Return
23rd Aug 20217:00 amRNSThree-year follow-up data for the ECLS trial
23rd Jul 20217:00 amRNSAgreement signed with major cancer center
22nd Jul 20217:00 amRNSValidation of ImmunoINSIGHTS service in COVID-19
1st Jul 20217:00 amRNSTotal Voting Rights
8th Jun 20217:00 amRNSFull Year Trading Update
28th May 20217:30 amRNSNotice of FY21 Trading Update
5th May 20217:03 amRNSReturn of China Rights to EarlyCDT

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.